Dr. Wassana Yantasee, CEO of PDX Pharmaceuticals, was selected as one of the 6 semi-finalists at the AIM-HI Women’s Venture Competition in Oncology (from among 72 female executives worldwide) by the panel of top cancer experts and VCs based on PDX Pharma’s innovative nano-platform to deliver cancer immunotherapies. The first drug candidate, ARAC-02, targets cancer and harnesses the immune system for cures and preventing relapse. The program promotes women entrepreneurship in oncology. The winner will receive up to $1M investment.